ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

February 2, 2018: By Joan McKenna

ReVision Optics, the maker of the Raindrop Near Vision Inlay, has closed its doors, the company announced on its website.

The announcement said the inlay would no longer be sold as of Jan. 30, 2018.

The move leaves the AcuFocus KAMRA as the only US FDA-approved corneal inlay available for the treatment of presbyopia.

The Raindrop gained US approval in June 2016 for correction of presbyopia in patients who have not had cataract surgery. It also achieved marketing authorization in the European Union, South Korea, Australia, and New Zealand.

The company announced in April 2017 that surgeons had implanted a thousand Raindrops since the product’s launch in late August 2016.

Privately held ReVision was headquartered in Lake Forest, California.

It set up a hotline that would be staffed through April 30, 2018, at 1-866-934-6592.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility